TerraPower Isotopes® announced that the company is building its flagship current Good Manufacturing Practices actinium-225 (ac-225) manufacturing facility in the Bellwether District of Philadelphia, Pennsylvania. TPI's development of an East Coast manufacturing facility, along with expanding capacity in its existing Everett, Washington will increase production capacity 20-fold and position the company as the premier global distributor of ac-225. The project features a multi-year buildout, with production of cGMP actinium-225 beginning in 2029.
TerraPower Isotopes is part of TerraPower, a nuclear innovation company that advances transformative technologies across energy and healthcare. TPI is transforming the fight against cancer by bringing the next generation of isotopes to market, and its actinium-225 is currently being utilized in human clinical trials around the world. This new cGMP Bellwether Laboratory will further expand ac-225's supply, certify the product with cGMP standards, and increase production levels overall to support growing global drug development needs.
"TerraPower's mission is to deliver new technologies to market that can improve lives; and the work our TerraPower Isotopes team is doing shows real promise in supporting the expansion of a diverse suite of cancer treatments using nuclear medicine," said TerraPower president and CEO Chris Levesque. "This new facility will help us increase the global supply of actinium-225 and increase access for researchers and drug developers who are advancing new cancer treatments."
"Today marks a major milestone for TerraPower Isotopes and for the future of precision medicine. This new facility is a testament to the demand for actinium-225 as part of the growing industry which is transforming how cancer is treated," said Scott Claunch, president of TerraPower Isotopes. "Our team is proud to be building a large-scale cGMP manufacturing facility in Philadelphia, which will play a pivotal role in expanding global access to this rare isotope."
TPI evaluated over 350 potential sites across the United States in a rigorous site selection process that included 49 site visits in eight metropolitan areas. The Bellwether District is uniquely positioned to offer the scale, proximity to critical infrastructure, and access to a robust life sciences and medical ecosystem that is critical to TPI and the radiopharmaceutical industry.